February 7, 2018 / 9:40 PM / 14 days ago

BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study

Feb 7 (Reuters) - Amicus Therapeutics Inc:

* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™

* AMICUS THERAPEUTICS INC - CONSISTENT AND DURABLE RESPONSES ACROSS KEY MEASURES OF SAFETY, FUNCTIONAL OUTCOMES AND BIOMARKERS OUT TO MONTH 12 IN TRIAL

* AMICUS THERAPEUTICS INC - VERY LOW RATE (<1%) OF INFUSION ASSOCIATED REACTIONS MAINTAINED AFTER 550+ INFUSIONS IN TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below